Your shopping cart is currently empty

HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity. HJB97 is a high-affinity inhibitor of BET (Kis: 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), 1.0 nM (BRD4 BD2), respectively).


| Description | HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity. HJB97 is a high-affinity inhibitor of BET (Kis: 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), 1.0 nM (BRD4 BD2), respectively). |
| Targets&IC50 | BRD4 BD2:1.0nM, BRD4 BD2:7.0nM, BRD3 BD1:0.18nM, BRD3 BD1:6.6nM, BRD2 BD1:0.9(ki), BRD2 BD1:3.1nM, BRD3 BD2:0.21nM, BRD3 BD2:1.9nM, Plusmn:0.01 nM (ki), Plusmn:0.03 nM (ki), Plusmn:0.09 nM (ki), Plusmn:0.1 nM (ki), Plusmn:0.2 nM, Plusmn:0.2 nM (ki), Plusmn:0.4 nM, Plusmn:0.5 nM, Plusmn:0.6 nM, Plusmn:0.7 nM, BRD2 BD2:0.27nM(ki), BRD2 BD2:3.9nM, BRD4 BD1:0.5nM, BRD4 BD1:7.0nM |
| In vitro | HJB97 is a highly potent BET inhibitor with IC50 values of 3.1 nM (BRD2 BD1), 3.9 nM (BRD2 BD2), 6.6 nM (BRD3 BD1), 1.9 nM (BRD3 BD2), and 7.0 nM for both BRD4 BD1 and BD2. At concentrations of 300-1000 nM, HJB97 effectively down-regulates c-Myc levels in RS4;11 cell lines within 24 hours. Additionally, HJB97 (10-1000 nM over 4 days) significantly inhibits cell growth in RS4;11 and MOLM-13 acute leukemia cell lines, with IC50 values of 24.1 nM and 25.6 nM, respectively[1]. |
| Molecular Weight | 500.55 |
| Formula | C26H28N8O3 |
| Cas No. | 2093391-24-1 |
| Smiles | CCn1nc(cc1Nc1nc(nc2[nH]c3cc(-c4c(C)noc4C)c(OC)cc3c12)C(=O)NC)C1CC1 |
| Relative Density. | 1.52 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27 mg/mL (53.94 mM), Sonication is recommended. H2O: insoluble | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.